Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc says its wholly-owned subsidiary KGK Sciences Inc, on behalf of its client Hofseth BioCare ASA (HBC), has received a no-objection acknowledgement letter from the US Food and Drug Administration (FDA) regarding the development of a new dietary ingredient dossier for its patented ProGo ingredient.
The company said HBC, a leading manufacturer of innovative marine-derived calcium, protein, collagen, and lipid nutritional supplements, is now part of an exclusive list of companies that have successfully notified the FDA of their new dietary ingredient.
The acknowledgement is the highest safety rating and attestation the client can receive for its dietary ingredient and to date, HBC’s entire portfolio of human food-grade ingredients has received the FDA’s “all good” letter, Wellbeing noted.
READ: Wellbeing Digital Sciences says subsidiary IRP Health’s new Toronto clinic has received approval from Veterans Affairs Canada for its Reactivation program
Wellbeing and KGK CEO Najla Guthrie said KGK has significant experience in helping its clients achieve their goals as shown by these high marks of achievement and market distinction.
“Consumers and retailers are starting to understand what it means to have an acknowledgement no-objection letter from the FDA,” Guthrie said. “Both can have confidence that the serving levels in these products are correctly chosen, based upon appropriate scientific methods, and rigorously reviewed by FDA scientists.”
HBC chief quality officer Angelika Florvaag added: “At HBC, we pride ourselves in producing superior health ingredients to enhance human health and quality of life, above and beyond what is currently available in the market today and KGK has enabled us to continuously meet that high standard.”
Wellbeing is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics.
A subsidiary of Wellbeing, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality research trials with a focus on nutraceutical and emerging health care products.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie